This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Crolibulin

Immune Pharmaceuticals Ltd.

Drug Names(s): EPC2407, Crinobulin

Description: EPC2407 is the first of a novel class of microtubulin inhibitors discovered by EpiCept. These compounds cause caspase activation, cell cycle arrest, and apoptotic death in cancer cells.

Deal Structure: EpiCept and Immune
In November 2012, Immune Pharmaceuticals and EpiCept announced that they have entered into a definitive merger agreement. The combined company is to be named Immune Pharmaceuticals. In August 2013, Immune announced the completion of the merger of Immune Pharmaceuticals and EpiCept.


Crolibulin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug